Company Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program.
The company was incorporated in 1987 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 22, 1992 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 17,000 |
| CEO | Daniel P. O'Day |
Contact Details
Address: 333 Lakeside Drive Foster City, California 94404 United States | |
| Phone | 650 574 3000 |
| Website | gilead.com |
Stock Details
| Ticker Symbol | GILD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882095 |
| CUSIP Number | 375558103 |
| ISIN Number | US3755581036 |
| Employer ID | 94-3047598 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Johanna Mercier | Chief Commercial and Corporate Affairs Officer |
| Jacquie Ross C.F.A. | Senior Vice President of Treasury and Investor Relations |
| Keeley Wettan | Executive Vice President and General Counsel of Legal and Compliance |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation and Portfolio |
| Dr. Flavius Martin M.D. | Executive Vice President of Research |
| Janet Dorling | Senior Vice President of Intercontinental Region and Global Patient Solutions |
| Bernard M. Fine M.D., Ph.D. | Vice President of Oncology and Franchise Head of Early Development |
| Dr. Stacey Y. Ma Ph.D. | Executive Vice President of Pharmaceutical Development and Manufacturing |
| Cindy Perettie | Executive Vice President of Kite |
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 144 | Filing |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 23, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 4 | Statement of changes in beneficial ownership of securities |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 12, 2026 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Feb 10, 2026 | 8-K | Current Report |
| Feb 5, 2026 | 144 | Filing |
| Feb 5, 2026 | SCHEDULE 13G | Filing |